Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Mar
3
2023
FDA Issues Draft Guidance on Labeling of Plant-Based Milk Alternatives Epstein Becker & Green, P.C.
Aug
22
2019
New York State Decriminalizes Possession of Marijuana Epstein Becker & Green, P.C.
Aug
13
2015
Telehealth / Remote Care 2.0: The Coming Disruption Epstein Becker & Green, P.C.
Feb
27
2020
Antitrust Byte: FDA and FTC Join Forces to Promote Biosimilars Epstein Becker & Green, P.C.
Mar
24
2020
FDA Eases Device Modification Rules to Expand Availability of Ventilators During COVID-19 Pandemic Epstein Becker & Green, P.C.
Jan
3
2024
Unpacking Averages: The Seasonality of FDA 510(k) Decision-Making and the Impact of Michigan Playing for a National Championship Epstein Becker & Green, P.C.
Apr
28
2020
Face or Fingerprint? The DEA Revisits Biometric Identifiers for e-Prescribing Controlled Substances Epstein Becker & Green, P.C.
Apr
2
2024
Unpacking Averages: Adverse Events for Device-Lead Combination Products Epstein Becker & Green, P.C.
Nov
1
2021
Unpacking Averages: Analyzing Descriptions from Cardiovascular Device Adverse Events Epstein Becker & Green, P.C.
Dec
1
2021
Unpacking Averages: Popular Ways to Combine Device Functionality Epstein Becker & Green, P.C.
Jul
16
2022
FDA Greenlights Pharmacists to Prescribe COVID-19 Drug Paxlovid Epstein Becker & Green, P.C.
Apr
3
2019
FDA Commissioner Gottlieb Says Agency Will Not Tolerate Deceptive Marketing of CBD Products; Issues Warning Letters Epstein Becker & Green, P.C.
Nov
22
2019
Limitations on Pre-Employment Testing for Marijuana Epstein Becker & Green, P.C.
Feb
2
2016
FDA Recommends Medical Device Manufacturers Implement a Comprehensive Cybersecurity Risk Management Program in Accordance with NIST Standards Epstein Becker & Green, P.C.
Mar
19
2020
FDA Issues Guidance for Ongoing Clinical Trials During COVID-19 Pandemic Epstein Becker & Green, P.C.
Jan
10
2017
New Federal and State Initiatives Seek to Combat Antimicrobial Resistance Epstein Becker & Green, P.C.
Jun
7
2017
Growing Questions About Employee Medical Marijuana Use Leave Employers in a Haze Epstein Becker & Green, P.C.
Nov
1
2021
New York DOL Issues FAQs on Recreational Cannabis – Guidance for Employers Epstein Becker & Green, P.C.
Oct
23
2018
CMS Unveils Proposed Rule Regarding Direct-to-Consumer Television Advertisements for Prescription Drug and Biological Products Epstein Becker & Green, P.C.
Dec
18
2018
Mixed Results for Employers on Marijuana – Two Federal Courts Refuse to Find State Marijuana Laws Preempted by Federal Law Epstein Becker & Green, P.C.
Aug
29
2019
Will the Growing Acceptance of Cannabis Send Drug-Screening Policies Up in Smoke? Epstein Becker & Green, P.C.
Jul
11
2023
Unpacking Averages: Searching for Bias in Word Embeddings Trained on FDA Regulatory Documents Epstein Becker & Green, P.C.
Oct
24
2023
Congress May Have a Vision for Psychedelic Regulation in the US Epstein Becker & Green, P.C.
Mar
24
2020
Medical Marijuana Deemed “Essential” During COVID-19 Pandemic Epstein Becker & Green, P.C.
Feb
7
2024
NJ Approves Cannabis Regulatory Amendment with Major Impacts on Class 5 Retail License Holders Epstein Becker & Green, P.C.
Mar
26
2024
Court Clarifies Employers’ Rights Under Connecticut’s Palliative Use of Marijuana Act, Guidance on Drug Testing Epstein Becker & Green, P.C.
Apr
11
2024
FDA Releases Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements Epstein Becker & Green, P.C.
Feb
13
2019
CBD “Edibles” Face Opposition from States, FDA Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins